News Hub | News Direct


Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Valeo Pharma secures $5M credit facility agreement with Accord Financial

Valeo Pharma Inc.

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share details the company has entered into a credit facility agreement with Accord Financial for a total of $5 million. The credit facility, backed by a first-ranking lien on the company's short-term assets, carries interest at the prime rate plus an applicable margin. The capital secured through this facility will enable Valeo Pharma to sustain its rapid growth trajectory without resorting to share dilution, safeguarding the interests of its shareholders. Valeo Pharma is a dynamic Canadian pharmaceutical company with a dedicated focus on the commercialization of innovative prescription products in Canada. The company's emphasis on respiratory/allergy, ophthalmology, and hospital specialty products underscores its commitment to delivering essential healthcare solutions. The credit facility is a strategic move that positions Valeo Pharma to continue its expansion efforts and meet the rising demand for innovative pharmaceutical products while preserving the value for its shareholders. Contact Details Proactive Investors +1 604-688-8158

September 27, 2023 01:48 PM Eastern Daylight Time

Article thumbnail News Release

Classiq to Host Quantum Software Hackathon and Bootcamp on October 1

Classiq Technologies

Classiq Technologies, a leading quantum computing software company, today announced its annual quantum computing software bootcamp and hackathon, the Classiq Quest. There is no cost to participate in either event. First up is the bootcamp, October 1-5, during which participants will learn how to fully exploit Classiq’s software to design, optimize and execute quantum algorithms. One to two hours of work per day over the five days will provide students, professors and others in academia focused on electrical engineering, computer science and other related fields an excellent opportunity to learn how to develop quantum algorithms. The quantum computing bootcamp is also a resource for those in industries such as DevOps, finance, chemistry, pharma, automotive and supply chain who want to learn how to harness the power of quantum computing. With a daily challenge on each day, participants will emerge from the bootcamp as experts on Classiq’s platform and fully prepared to tackle the Quest Hackathon challenges. Next up is the Classiq Quest Hackathon, which runs from October 8-11. The hackathon is an online programming competition open to individual as well as group participants. It is designed to reward those that can create efficient and elegant quantum circuits for a variety of important problems. Over the four days, participants receive a series of challenges for which they must design, optimize, and execute quantum algorithms. The challenges are a combination of open and well-defined problems that fall under three quantum computing themes – applications, utility, and education – and for each theme, there are two challenges. The application challenges focus on the use of quantum algorithms for addressing real-life problems in industries such as chemistry, finance, material science, and cyber security. Quantum utility concentrates on quantum algorithms that fully exploit the capabilities of available quantum computers. The quantum education theme is targeted at quantum algorithms for educational purposes with intuitive graphics and visualizations. “We often hear from professors that they have difficulty finding ways to teach students about quantum computing,” said Amir Naveh, chief product officer and co-founder at Classiq. “Our bootcamp offers a great way for students to get up to speed quickly on quantum computing and then test their skills with the challenges in the hackathon. It’s equally relevant and useful for people on the corporate side, who are quantum curious and need an easy entry point. We’re all about democratizing quantum computing.” Last year, nearly 300 participants from 51 countries registered for the Classiq coding competition and Classiq received more than 150 solutions. Participants must register by Sunday, October 1. Details on events, challenges and ways to participate are available at The prize pool is $15,000. For each challenge, the first, second and third place winners will be rewarded with $1,500, $700, and $300, respectively. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing software platform with a single point of entry into quantum computing, from algorithm design to execution. Tailored to all levels of developer proficiency, Classiq aims to democratize access to quantum computing with software that equips customers to take full advantage of the quantum computing revolution. A low-code development environment ensures that a broader range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of how to program quantum computer hardware. Backed by powerful investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking software development platform. Follow Classiq on LinkedIn, X (formerly Twitter), or YouTube, or visit to learn more. Contact Details Michelle Allard McMahon/Jenna Beaucage Company Website

September 27, 2023 01:45 PM Eastern Daylight Time

Article thumbnail News Release

Roberts & Ryan Inc., America's first Service-Disabled Veteran-Owned (SDVO) broker-dealer, is pleased to welcome Major General Austin “Sparky” Renforth (Ret.) as their latest Senior Advisor.

Roberts & Ryan, Inc.

Major General Austin Renforth (Ret.) joins Roberts & Ryan as a veteran of the United States Marine Corps. Over the course of his 40-year military career Maj. Gen. Renforth has held a variety of leadership and command positions. Maj. Gen. Renforth enlisted in the United States Navy in 1982. After two years in the Navy, he received an appointment to the United States Naval Academy, graduating with a BS degree in Mathematics and receiving a commission as a Second Lieutenant in the United States Marine Corps. Maj. Gen. Renforth has had the privilege of command at every level. He served as a Rifle Platoon, Heavy Machinegun Platoon, and Dragon Platoon Commander at 1st Battalion, 2nd Marines, participating in Operation DESERT SHIELD/STORM. He also served as a Platoon Commander at 2nd Light Armored Infantry Battalion and deployed as a Detachment Commander with 2nd Battalion, 2nd Marines in support of Operation PROVIDE PROMISE. Maj. Gen. Renforth commanded rifle companies at 1st Battalion, 2nd Marines and 2nd Battalion, 6th Marines. At the battalion level, he commanded the Maritime Special Purpose Force while deployed with the 31st Marine Expeditionary Unit. Later, he commanded 2nd Light Armored Reconnaissance Battalion and deployed twice in support of Operation IRAQI FREEDOM. He later assumed command of 7th Marine Regiment and deployed in support of Operation ENDURING FREEDOM. Afterwards, he was Commanding General of Training Command, and then Commanding General of Marine Corps Recruit Depot Parris Island and Eastern Recruiting Region. He again deployed to Iraq as the Commanding General of Task Force Iraq in support of Operation Inherent Resolve. Maj. Gen. Renforth’s staff assignments include tours as Protocol Officer, US Central Command; Operations Officer 2nd Battalion, 6th Marines; Faculty Advisor, Amphibious Warfare School; Executive Officer, 2nd Battalion, 4th Marines and deployed to Okinawa, Japan; Operations Officer, 5th Marines; Operations Officer, Regimental Combat Team 1 and deployed in support of Operation IRAQI FREEDOM in Fallujah; Branch Chief, Special Plans Branch, J-5, US Northern Command; and Chief of Staff, 1st Marine Division. Additionally, Maj. Gen. Renforth served as the Chief of Staff NORAD and USNORTHCOM in Colorado Springs. Most recently Maj. Gen. Renforth was the Commanding General of the Marine Corps Air Ground Combat Center and the Marine Corps Air Ground Training Command. Maj. Gen. Renforth is a graduate of The Basic School, the Infantry Officer Course, Amphibious Warfare School, Armed Forces Staff College, NATO Defense College in Rome, Italy, and the High Command and Staff Course in the United Kingdom. Maj. Gen Renforth was a member of the Marine Corps Rugby Team, has worked as the Head Coach for the Naval Academy Sprint Football Team, and as an assistant coach for the Navy Division 1 Men’s Rugby Team. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations since 2018, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, primarily focusing on general wellness, mental health, and career transition. Contact Details Michael C. Del Priore +1 646-859-4061 Company Website

September 27, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant

NanoViricides, Inc.

By David Willey, Benzinga Read the latest report on NanoViricides here The CDC recently issued a warning that Respiratory Syncytial Virus (RSV), a common and highly contagious lung infection that can cause bronchitis and pneumonia, is on the rise in the Southeastern United States – and the very young and the elderly are the most at risk of developing severe incidences of RSV. Every year, there are over 2 million outpatient (non-hospitalized) cases of RSV in children under 5, and RSV is the leading cause of hospitalizations for young children. There are up to 80,000 hospitalization cases for children under 5, and there are also up to 160,000 cases of patients over 65 getting hospitalized with RSV. Up to 300 children under 5 and 10,000 adults over 65 die of RSV annually. Despite this serious disease, there were no vaccines or good treatment options until recently. The recently approved vaccines from GSK plc (NYSE: GSK) and Pfizer (NYSE: PFE) also have severe limitations. These vaccines are only for use in patients aged 60 and over. However, these vaccines can involve side effects, including atrial fibrillation, Guillain-Barré syndrome and another potentially related disorder. A recently approved vaccine for pregnant women to protect the newborn infant upon birth has the risk of preterm births. In July 2023, the FDA also approved Beyfortus, an antibody treatment for children delivered as an injection to help prevent the development of RSV. Beyfortus was developed by Sanofi (NASDAQ: SNY) and AstraZeneca (NASDAQ: AZN). It is expected to be better than a previously approved antibody (palivizumab, trade name Synagis, developed by MedImmune, now marketed by SOBI – Swedish Orphan Biovitrum) for the same indication. Like the vaccines, however, there are side effects associated with these protective antibody treatments, which can include anaphylaxis, a severe allergic reaction. Yet, there are no treatments for RSV infection except for severe hospitalized cases when children at risk of dying are given the toxic drug ribavirin at very high doses as a last resort. The market for therapeutics for RSV was worth $1.8 billion in 2022 and will reach $8.73 billion by 2031 at a compound annual growth rate (CAGR) of 18.9% during the forecast period, according to a recent report from Growth Plus Therapeutics. Note that there were no real treatments, only one protective antibody, Synagis, available in 2022. The therapeutic used for treating RSV is Ribavirin, a highly toxic compound also used as a therapy for hepatitis C. However, Ribavirin carries with it some severe side effects, including the destruction of red blood cells, leading to liver, kidney and spleen toxicities and failures – which limit its use to patients with a high risk of progressively severe RSV. The primary concerning side effect of Ribavirin is anemia, a decrease in red blood cells that can cause a drop in hemoglobin. Ribavirin-induced anemia can manifest within two weeks of starting the therapy and can get worse as the drug dosage increases. NanoViricides Treatment For RSV NanoViricides (NYSE American: NNVC), a leading developer of antiviral treatments through its nanomedicines platform, is developing a safe and effective alternative therapeutic for RSV. Its drug candidate, NV-387, has already been shown to not have the toxicity or side effects associated with Ribavirin, according to the company. It reports that in the recent pre-clinical animal study, NV-387 almost matched the efficacy of Ribavirin with no toxicity. This animal study was designed to mimic the lethal lung pneumonia in infants caused by RSV infection. Importantly, NV-387 is already in phase 1 human clinical trials as the active ingredient in the company’s COVID drug candidate NV-CoV-2. The company has just reported that it was found to be completely safe, with no side effects found to date, in this continuing phase 1 Study. For this reason, the company anticipates soon being able to advance NV-387 to a phase 2 human clinical trial against RSV. If the results of animal studies are replicated in humans, this nanoviricides drug could become truly a game-changer in the treatment of RSV infections. Learn more about NanoViricides’ NV-387 antiviral here. About NanoViricides NanoViricides, Inc. (the "Company") ( is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 Company Website

September 27, 2023 08:45 AM Eastern Daylight Time

Article thumbnail News Release

Graft Polymer's new Slovenian plant key to unlocking industrial-scale solutions

Graft Polymer (UK) PLC

Welcome to Wednesday's business update. In this video, we focus on Graft Polymer (UK) PLC's milestone—the commissioning of its expanded Slovenian plant. Chairman Roby Zomer says this new facility doubles the company's production capacity to 6,000 tonnes per year and opens doors for industrial-scale partnerships. We'll also delve into the company's recent contract achievements, including a significant U.S. approval for its GraftBio drug delivery system. Where it has been approved for sale over-the- counter as a part of the MGC Pharma ArtemiC COVID treatment. Stay tuned as we explore how these developments are setting the stage for Graft Polymer's future growth and market expansion. The core business of the group comprises polymer modification and drug delivery system developments. The group has developed a proprietary set of polymer modification technologies which uses recycled raw materials and a closed loop system to reduce waste. Towards the end, we'll touch upon the financials, examining the 27% drop in revenue to £240,000 and the 35% increase in operating losses to £1.03 million during this pivotal transition period. For more information on the company, and to see interviews with the Chairman, Roby Zomer, visit: Contact Details Proactive UK Ltd +44 20 7989 0813

September 27, 2023 08:06 AM Eastern Daylight Time

Article thumbnail News Release

Magdalena Biosciences JV with Filament Health and Jaguar Health completes coca leaf import

Filament Health Corp

Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to announce a significant development involving Magdalena Biosciences, a joint venture established by Filament Health and Jaguar Health. The development pertains to the successful import of coca leaf to Filament's Metro Vancouver research and development facility. Lightburn explained that the import was authorized by the Peruvian Health Authority and was sourced from the only company in Peru authorized to collect, distribute, and export coca leaf and its derived products. The imported coca leaves were received by Psilo Scientific, a wholly-owned subsidiary of Filament Health. These coca leaves will be utilized for initial research purposes, focusing on exploring neuropsychiatric indications. Magdalena Biosciences and Filament Health are currently in the process of seeking full compliance with the Nagoya Protocol in Peru. The Nagoya Protocol is an international agreement designed to ensure the fair and equitable sharing of benefits arising from the utilization of genetic resources and associated traditional knowledge held by indigenous and local communities. This development highlights Filament Health's commitment to advancing its research initiatives and exploring the therapeutic potential of natural resources, while also ensuring compliance with international agreements and ethical considerations. The research conducted through this joint venture has the potential to contribute valuable insights to the field of neuropsychiatric indications, ultimately benefiting patients and the broader healthcare industry. Contact Details Proactive Investors +1 604-688-8158

September 25, 2023 01:49 PM Eastern Daylight Time

Article thumbnail News Release

A Very Important Change Is Coming for Airplane Bathrooms


A video accompanying this announcement is available at: The Department of Transportation (DOT) is making larger single-aisle airplanes more accessible by requiring accessible lavatories for people with disabilities. While this rule will be implemented over the coming years, it is a monumental achievement for the disability civil rights movement. Under previous standards, people who use wheelchairs have no way to access the restroom on single-aisle aircraft. They are forced them to dehydrate themselves, or even soil themselves, before flights – causing major bodily harm! Over the past 75 years, Paralyzed Veterans of America (PVA) has led the fight for accessibility — and air travel is no different. PVA helped pass the landmark legislation to first make air travel accessible over 35 years ago, and they played an integral role in securing accessible airplane lavatories. They continue to advocate for additional reforms that will ensure a safe, dignified air travel experience for people with disabilities. So, what does this new rule mean for the future of accessible air travel? And what else is needed to make the air travel experience fully accessible for people with disabilities? Now is an opportunity for your audience to learn more about the new rule and the ways Paralyzed Veterans of America (PVA) has helped secure this monumental achievement, and how they continue to advocate for other meaningful reforms related to the upcoming renewal of the Federal Aviation Administration. A nationwide media tour was conducted featuring Chief Policy Officer at Paralyzed Veterans of America, Heather Ansley discussing the new lavatory rule and additional reforms that must be made to make air travel fully accessible through the reauthorization of the FAA. Additional topics that were discussed included: What the new Department of Transportation rules will do. What this means for the disability community. Why this DOT rule was desperately needed. The reasons why air travel is so far behind basic standards. What else needs to be done to ensure air travel is accessible. PVA remains on the forefront of the disability civil rights movement – fighting for stronger ADA enforcement, expanding support for home-based care, and more. To join PVA’s fight for greater enforcement of the ADA, visit, or for air travel, visit About Paralyzed Veterans of America Paralyzed Veterans of America is a 501(c)(3) non-profit and the only congressionally chartered veterans service organization dedicated solely for the benefit and representation of veterans with spinal cord injury or diseases. The organization ensures veterans receive the benefits earned through service to our nation; monitors their care in VA spinal cord injury units; and funds research and education in the search for a cure and improved care for individuals with paralysis. As a life-long partner and advocate for veterans and all people with disabilities, PVA also develops training and career services, works to ensure accessibility in public buildings and spaces, and provides health and rehabilitation opportunities through sports and recreation. With more than 70 offices and 33 chapters, Paralyzed Veterans of America serves veterans, their families, and their caregivers in all 50 states, the District of Columbia, and Puerto Rico. Learn more at Contact Details YourUpdateTV +1 212-736-2727

September 25, 2023 10:40 AM Eastern Daylight Time

Article thumbnail News Release

Oxford Cannabinoid Technologies reports no adverse events in OCT461201 trial

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) chief executive Clarissa Sowemimo-Coker speaks to Thomas Warner from Proactive London after the pharmaceutical group announced it has successfully administered the final dose of its lead drug candidate, OCT461201, as part of its phase I clinical trial. Sowemimo-Coker says that no adverse events were reported during the trial, which began in late July. While awaiting the final report, the company remains optimistic about the results. She briefly touches upon the potential move into phase two studies for the compound, saying that external advisor Dr William Paul Farquhar-Smith and Chief Medical Officer Dr. Tim Corn are actively planning these next steps. Additionally, the company's AGM is slated for Thursday, presenting another opportunity for shareholder engagement. Oxford Cannabinoid Technologies is a pharmaceutical group developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market. The group is developing OCT461201 as a potential treatment for chemotherapy-induced peripheral neuralgia (CIPN). Contact Details Proactive UK Ltd +44 20 7989 0813

September 25, 2023 06:00 AM Eastern Daylight Time

Article thumbnail News Release

Lophos Pharmaceuticals announces company is now trading on the CSE under the ticker MESC

Lophos Pharmaceuticals

Lophos Pharmaceuticals CEO Claire Stawnyczy joined Steve Darling from Proactive to share the news that the company which specializes in the cultivation, research, and sale of Lophophora williamsii or peyote cactus has achieved significant milestones. Lophos Pharma has commenced trading on the Canadian Securities Exchange (CSE) under the ticker symbol "MESC." This development marks a significant step for the company in terms of visibility and accessibility to investors. The company has successfully obtained a Controlled Substances Dealers License from Health Canada. This license empowers Lophos Pharma to engage in various activities related to controlled substances, including possession, production, sale/provision, sending, transportation, and delivery. The controlled substances covered by this license include mescaline, psilocin, and psilocybin. Lophos Pharma has entered into a strategic partnership with KGK Science to explore potential pathways to market sustainably grown, peyote-derived natural health products. While peyote itself is legally recognized in Canada, mescaline—the psychoactive compound derived from the peyote cactus—remains classified as a Schedule 3 controlled substance. These developments underscore Lophos Pharma's commitment to advancing its unique position in the emerging market of natural health products derived from peyote. The company's ability to obtain a Controlled Substances Dealers License is particularly noteworthy, as it positions Lophos Pharma to engage in research, production, and distribution of controlled substances in compliance with Canadian regulations. As Lophos Pharma continues its work in researching and developing peyote-derived products, its collaboration with KGK Science represents a key partnership to explore the potential for sustainable and legal market opportunities in this evolving sector. Contact Details Proactive Investors +1 604-688-8158

September 22, 2023 01:34 PM Eastern Daylight Time

12345 ... 217